Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988;35(5):529-34.
doi: 10.1007/BF00558249.

Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)

Affiliations
Clinical Trial

Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)

M Colle et al. Eur J Clin Pharmacol. 1988.

Abstract

Three groups of eight healthy male volunteers received placebo for 2 days, then daily morning doses either of cimetidine 800 mg, ramixotidine 750 mg (CM 57755A), or placebo, for 14 days, and then were all returned to placebo for one more day. Plasma levels of prolactin, testosterone and 17 beta-estradiol were measured on Days 2, 3, 16 and 17 in blood samples taken 30 and 15 min before and 0, 60, 120, 180, 240 and 300 min after treatment. Gastrin was assayed in blood collected on the same days 180 min after treatment. Mean pre- and post-treatment areas under the time-concentration curves of the first three hormones were not significantly different in the three groups on any test day, or within the same group throughout the four test days. Mean plasma gastrin levels ranged between 27 and 42 pg/ml, respectively, in the placebo and cimetidine treated groups on test day 3, and intermediate values were found in the group receiving CM 57755A. There was no statistically significant difference in gastrin level between the groups on any test day or within the same group throughout the four test days. No subjective side-effects attributable to the treatments were reported, and there were no abnormalities in blood pressure, heart rate or standard laboratory tests.

PubMed Disclaimer

Similar articles

Cited by

  • Safety of acid-suppressing drugs.
    Smallwood RA, Berlin RG, Castagnoli N, Festen HP, Hawkey CJ, Lam SK, Langman MJ, Lundborg P, Parkinson A. Smallwood RA, et al. Dig Dis Sci. 1995 Feb;40(2 Suppl):63S-80S. doi: 10.1007/BF02214872. Dig Dis Sci. 1995. PMID: 7859585 Review.

References

    1. Lancet. 1977 Oct 8;2(8041):761 - PubMed
    1. Lancet. 1978 Sep 16;2(8090):635 - PubMed
    1. Gastroenterology. 1979 Mar;76(3):504-8 - PubMed
    1. Scand J Gastroenterol. 1986 Jan;21(1):123-8 - PubMed
    1. Dig Dis Sci. 1979 Jun;24(6):468-70 - PubMed

Publication types

LinkOut - more resources